Urolithin A,
does it really help with Slower biological aging and longer healthspan and lifespan in healthy adults?
research showsUrolithin A for slowing biological aging or extending healthspan and lifespan in healthy adults is rated ?. Human randomized trials exist, but they assess different outcomes. A 2022 trial in 66 participants over four months found no significant benefit for its co-primary six-minute walk and muscle ATP-production outcomes, with only some secondary signals for muscle endurance and mitochondrial-related blood markers. A 2025 four-week trial in 50 participants changed immune-cell composition and metabolic function but did not assess a validated whole-person pace of biological aging, multisystem healthspan, disease-free survival, or mortality. Lifespan was directly extended only in C. elegans, while rodent work assessed muscle function. Muscle endurance and immune biomarkers are different efficacy axes, so the absence of direct human aging-rate, healthspan, or lifespan efficacy literature gives ? with a null score. Short-term tolerability is separate from long-term aging efficacy and safety.
ads claimMarketing can connect clearing damaged mitochondria, making cells younger, or reversing immune aging to a lower human biological age and longer healthspan or lifespan. Mitophagy signaling, immune-cell proportions, plasma metabolites, and muscle endurance are not validated aging-rate or survival outcomes.
Useful facts when choosing a product
- Urolithin A is produced when some gut microbiomes metabolize ellagic-acid-related food compounds, while Mitopure is a specific standardized ingredient intended for direct intake.
- Human trials commonly used 500 to 1,000 mg daily for four weeks to four months, but no dose or duration is established for slowing aging or extending healthspan or lifespan.
- The purity and formulation of a branded trial ingredient cannot be assumed to match the actual content, contaminants, or bioavailability of retail supplements, so product variation should not be generalized into efficacy.
- Short trials generally reported tolerability, but safety data are limited for use over years, pregnancy or lactation, severe liver or kidney disease, and combinations with multiple medicines.
What the research actually shows
Liu and colleagues randomized 66 adults aged 65 to 90 years to urolithin A 1,000 mg daily or placebo for four months. The co-primary six-minute walk and maximal hand-muscle ATP-production outcomes did not improve significantly versus placebo. Repeated-contraction endurance in hand and leg muscles at two months and some acylcarnitine, ceramide, and CRP outcomes at four months were positive, but the four-month between-group endurance difference was nonsignificant as placebo also improved. Denk and colleagues gave 1,000 mg daily for four weeks to 50 healthy middle-aged adults and found changes in peripheral CD8 T-cell composition, fatty-acid oxidation, and other immune markers. Amazentis, the maker of Mitopure, funded and supplied both trials and participated in design or analysis. The lifespan result from Ryu and colleagues came from worms, not human survival.
Why this is classified as ?
The four-month randomized trial in 66 participants was null on its co-primary functional and ATP outcomes and positive only on some secondary muscle-endurance and mitochondrial markers. The four-week trial in 50 participants assessed immune-cell and metabolic markers rather than validated biological aging rate, multisystem healthspan, disease-free survival, or mortality. Direct positive lifespan evidence is limited to C. elegans, and human trials are manufacturer concentrated. No direct human efficacy literature for the stated claim gives ? with a null score.
Counterpoint. Changing the verdict requires an independent long randomized trial with prespecified validated aging pace, multisystem outcomes such as frailty, cognition, and mobility, disease-free survival, or mortality. Muscle-endurance efficacy belongs to a separate C-rated axis, as in existing entries 246 and 761, and cannot be repurposed as lifespan evidence.
Rejudgment record. New verdict — Applied ? with a null score because the four-month 66-person trial was null for its co-primary six-minute-walk and maximal-ATP outcomes and positive only for some secondary muscle or mitochondrial markers, the four-week 50-person trial assessed immune-cell and metabolic markers, and direct positive lifespan evidence was confined to C. elegans, leaving no human efficacy literature for validated biological aging rate, healthspan, disease-free survival, or mortality
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Slower biological aging in healthy adults | ? | Trials of muscle, mitochondrial, and immune surrogates exist, but no human efficacy literature directly assessed a validated whole-person pace of aging. |
| Longer healthspan in healthy adults | ? | No randomized trial was identified that followed multisystem function such as frailty, cognition, and mobility together with disease-free survival over the long term. |
| Longer lifespan in healthy adults | ? | Direct positive lifespan evidence comes from C. elegans, with no human efficacy trial assessing overall survival or mortality. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Liu S et al. 2022 | Four-month randomized double-blind placebo-controlled trial | 33 | Funded and supplied by Amazentis SA, which participated from design through publication decision; company employees and officers were authors | Co-primary six-minute walk and maximal ATP production, with secondary muscle endurance and plasma metabolic markers | Co-primary outcomes were not significant versus placebo, while two-month muscle endurance and some four-month metabolic markers were positive. | Different muscle and mitochondrial axis; null primary outcomes and manufacturer concentration |
| Denk D et al. 2025 | Four-week randomized double-blind placebo-controlled immune-marker trial | 50 | Funded by Amazentis SA, which supplied Mitopure; company employees and its president were authors | Peripheral T-cell subsets, immune-cell metabolism, function, and mitochondrial markers | Some CD8 T-cell composition and fatty-acid oxidation outcomes improved, but whole-person aging rate, healthspan, and survival were not assessed. | Positive immune-aging-related surrogates; short, manufacturer concentrated, and not direct for the claim |
| Ryu D et al. 2016 | Preclinical C. elegans lifespan and rodent muscle-function study | 0 | Amazentis-affiliated authors participated; detailed funding was not reported in the PubMed abstract | Worm lifespan and mitophagy, and muscle function in aging rodents | Worm lifespan and rodent muscle function improved, but these were not human lifespan or healthspan outcomes. | Mechanistic and preclinical lifespan signal with no direct human relevance to the claim |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-22).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-22 · Corrections: none
Cite this verdict
[Chamgap] Urolithin A x slower biological aging and longer healthspan and lifespan in healthy adults — Evidence Grade ?. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/antioxidant-aging/urolithin-a-healthy-adults-aging-healthspan-lifespan/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.